Innovation & Resilience of Biopharma Stocks

"The skilled healthcare worker shortage accelerated during the pandemic caused the next public health crisis. This is driving the need for more automation, A.I., digitization, and robotics. Some companies took off during the pandemic and are very well positioned to reap the benefits of that innovation moving forward," says Nina Deka. "Inflation should not affect the big biopharma group as much as most industries. Big biopharma firms see less than 1% of sales from Ukraine and Russia, making the war less impactful. Prescription drug demand is highly inelastic, which lends stability regardless of potential recessionary pressures," Damien Conover adds.